-
Key progress has been achieved in many clinical trials of Abexinostat.
Industry Data
Jianghuzhiyuan/PharmaSourcesJune 27, 2023
How much progress has been made in the research and development of HDAC inhibitor?
-
Pharmaceutical International Cooperation Under the New Drug Policies in China By ChatGPT
Industry Data
ChatGPT/PharmaSourcesSeptember 11, 2023
The business environment for pharmaceutical companies in China is generally favorable. China has a large population and a growing middle class, which creates a significant demand for healthcare and pharmaceutical products.
-
Under the new policy tilt, how can MNCs increase their investment in China?
Industry Data
Yefenghong/PharmaSourcesSeptember 08, 2023
On August 13th, the State Council issued the "Opinions on Further Optimizing the Foreign Investment Environment and Increasing the Attractiveness of Foreign Investment" (hereinafter referred to as the "Opinions").
-
Chinese Produced ASO Drug Innovation Therapy for Functional Cure of Chronic Hepatitis B Has Obtained FDA Clinical Approval
Industry Data
Xiaoyaowan/PharmasourcesSeptember 08, 2023
Recently, Haobo Pharmaceuticals announced that their investigational antisense oligonucleotide (ASO) drug AHB-137 has received clinical trial approval from the FDA in the United States for use in patients with chronic hepatitis B.
-
Research progress on the biological activity and pharmacological mechanism of naringin
Industry Data
Xiaomichong/PharmaSourcesSeptember 07, 2023
Naringin is a natural flavonoid compound. It is a colorless needle-shaped crystalline powder that is insoluble in cold water and extremely bitter in taste. Modern pharmacological studies have found that naringin has various therapeutic effects.
-
An Overview of the Research Advancements in Bispecific Antibodies
Industry Data
Dopine/PharmaSourcesAugust 30, 2023
According to the Pharmacodia Database, currently, there have been 13 drugs approved worldwide in this field. However, Removab was withdrawn from the market in 2017 due to its strong immunogenicity and commercial reasons.
-
With Whole Line Reduction or R&D Difficulties, Projects of Billions of Dollars Are Stranded - Analysis on Transnational Pharmaceutical Companies Terminating R&D Projects in H1 of the Year
Industry Data
PharmaSources/Spuer 203August 28, 2023
-
Sales volume of Dupixent reaching USD 5.35 billion in H1 of the year, setting off a R&D boom of IL-4R in China
Industry Data
PharmaSources/YefenghongAugust 28, 2023
Under the influence of Dupixent, there is a R&D boom of IL-4 targets in China.
-
FTC’s Antitrust Intensifies, Where Does Pharmaceutical Innovation Go?
Industry Data
PharmaSources/XiaobingAugust 23, 2023
In fact, the FTC has more than once blocked MNC’s mergers and acquisitions under the name of “antitrust”. So, what impact will this have on the US pharmaceutical ecosystem? What challenges does it pose to domestic innovative drugs going global?
-
35 per 100 CNY Earned for Marketing, How Much is the Sales Expense Ratio of Chinese Pharmaceutical Companies?
Industry Data
PharmaSources/CaicaiAugust 17, 2023
High sales expenses not only increase the cost of medical treatment and medication, but also affect the healthy development of the domestic pharmaceutical industry. Therefore, anti-corruption is imperative and imminent.
How much progress has been made in the research and development of HDAC inhibitor?
The business environment for pharmaceutical companies in China is generally favorable. China has a large population and a growing middle class, which creates a significant demand for healthcare and pharmaceutical products.
On August 13th, the State Council issued the "Opinions on Further Optimizing the Foreign Investment Environment and Increasing the Attractiveness of Foreign Investment" (hereinafter referred to as the "Opinions").
Recently, Haobo Pharmaceuticals announced that their investigational antisense oligonucleotide (ASO) drug AHB-137 has received clinical trial approval from the FDA in the United States for use in patients with chronic hepatitis B.
Naringin is a natural flavonoid compound. It is a colorless needle-shaped crystalline powder that is insoluble in cold water and extremely bitter in taste. Modern pharmacological studies have found that naringin has various therapeutic effects.
According to the Pharmacodia Database, currently, there have been 13 drugs approved worldwide in this field. However, Removab was withdrawn from the market in 2017 due to its strong immunogenicity and commercial reasons.
Under the influence of Dupixent, there is a R&D boom of IL-4 targets in China.
In fact, the FTC has more than once blocked MNC’s mergers and acquisitions under the name of “antitrust”. So, what impact will this have on the US pharmaceutical ecosystem? What challenges does it pose to domestic innovative drugs going global?
High sales expenses not only increase the cost of medical treatment and medication, but also affect the healthy development of the domestic pharmaceutical industry. Therefore, anti-corruption is imperative and imminent.
Pharma Sources Insight APRIL 2023
